Pfizer to Acquire Metsera for $4.9-$7.3B, Boosting Obesity Drug Pipeline

Pfizer's deal for Metsera could revolutionize obesity treatments. The acquisition comes as Pfizer faces patent cliffs and seeks new growth opportunities.

, and Administrator

2025 October 6 . 8:05 AM

1 min read

There is a pharmacy store and there is a vehicle in front of it and there is a building in the left... — There is a pharmacy store and there is a vehicle in front of it and there is a building in the left corner.

Pfizer to Acquire Metsera for $4.9-$7.3B, Boosting Obesity Drug Pipeline

Pfizer is set to acquire Metsera, a clinical-stage biotech company specializing in weight loss treatments, in a deal valued at $4.9 billion to $7.3 billion. The all-cash acquisition, expected to close in the fourth quarter of 2025, will see Pfizer pay $47.50 per Metsera share, with potential additional milestone payments of up to $22.50 per share for Metsera shareholders.

Metsera's leading drug candidate, MET-097i, is currently in phase 2 clinical trials for weight loss. Pfizer aims to enter the next-generation obesity drug development race with this acquisition, as the global market for obesity drugs is projected to grow significantly, from around $15 billion in 2024 to $150 billion in 2035.

Pfizer's interest in Metsera comes amidst its own patent cliff for blockbuster drugs like Eliquis and Ibrance. The company's long-term debt has increased in recent years due to acquisitions, including this one. Notably, Pfizer's own GLP-1 drug program, danuglipron, was discontinued in April 2025 due to liver injury in a patient trial.

The acquisition of Metsera by Pfizer is expected to bolster the company's pipeline in the growing obesity drug market. As the deal closes in the fourth quarter of 2025, Pfizer will gain access to Metsera's promising drug candidate and expertise in weight loss treatments, potentially leading to innovative new therapies in the future.